Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update

Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw a large growth in short interest in February. As of February 27th, there was short interest totaling 815,248 shares, a growth of 37.7% from the February 12th total of 592,027 shares. Currently, 4.9% of the shares of the company are sold short. Based on an average daily volume of 106,872 shares, the short-interest ratio is currently 7.6 days. Based on an average daily volume of 106,872 shares, the short-interest ratio is currently 7.6 days. Currently, 4.9% of the shares of the company are sold short.

Lyell Immunopharma Stock Performance

Shares of Lyell Immunopharma stock traded down $3.52 during trading hours on Friday, reaching $21.25. 141,870 shares of the company were exchanged, compared to its average volume of 114,906. The firm has a market cap of $451.35 million, a PE ratio of -1.30 and a beta of -0.14. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $45.00. The stock’s fifty day moving average is $24.13 and its 200 day moving average is $21.47.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Thursday, March 12th. The company reported ($7.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.15) by ($5.53). Lyell Immunopharma had a negative net margin of 762,355.56% and a negative return on equity of 85.36%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.02 million. Research analysts expect that Lyell Immunopharma will post -0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

LYEL has been the subject of several research reports. Citizens Jmp assumed coverage on Lyell Immunopharma in a research note on Monday, March 9th. They set a “market outperform” rating and a $34.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. Finally, HC Wainwright upgraded shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and lifted their price target for the company from $20.00 to $45.00 in a research report on Tuesday, December 9th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $39.50.

Insider Transactions at Lyell Immunopharma

In other Lyell Immunopharma news, insider Gary K. Lee sold 1,671 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $39,084.69. Following the sale, the insider owned 16,938 shares in the company, valued at approximately $396,179.82. The trade was a 8.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Lynn Seely sold 7,455 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $174,372.45. Following the completion of the transaction, the chief executive officer directly owned 74,266 shares of the company’s stock, valued at $1,737,081.74. The trade was a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 11,310 shares of company stock worth $264,285. Company insiders own 22.30% of the company’s stock.

Institutional Trading of Lyell Immunopharma

A number of institutional investors have recently bought and sold shares of LYEL. ARCH Venture Management LLC purchased a new position in shares of Lyell Immunopharma in the 2nd quarter valued at about $16,113,000. GSK plc purchased a new stake in Lyell Immunopharma during the fourth quarter worth approximately $46,560,000. MWG Caph Ltd acquired a new position in Lyell Immunopharma in the fourth quarter valued at approximately $31,030,000. Acadian Asset Management LLC increased its stake in Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after purchasing an additional 443,614 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Lyell Immunopharma by 76.0% in the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after purchasing an additional 336,378 shares during the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.